Biogenera is pleased to announce the appointment of Massimiliano Cesarini as Chief Executive Officer and Chairman of the Board.
With a strong background in Life Sciences and a track record of leadership across the pharmaceutical and biotech sectors, Cesarini brings extensive experience in managing complex operations, international teams, and high-impact strategic projects. His profile combines scientific vision with a results-driven approach focused on innovation, sustainability, and long-term value creation.
A Strategic Moment for Biogenera
Massimiliano Cesarini’s arrival marks a key turning point for Biogenera, as the company prepares to launch its first Phase I clinical trial for BGA002, a first-in-class anti-gene oligonucleotide targeting the MYCN oncogene, a major driver of aggressive pediatric and adult cancers.
Under his leadership, Biogenera aims to:
- Strengthen its position in the European biotech ecosystem
- Expand its global network of strategic and scientific partnerships
- Advance the MyGenera™ platform and broaden its therapeutic pipeline
“Sono entusiasta di entrare in un’azienda che rappresenta un’eccellenza italiana nella ricerca biotecnologica. Credo fortemente nel potenziale scientifico di Biogenera e nella sua capacità di portare soluzioni concrete dove oggi la medicina ha ancora bisogno di fare passi avanti.”
– Massimiliano Cesarini, CEO di Biogenera
Leading the Future of Precision Therapies
Cesarini’s appointment reinforces Biogenera’s commitment to becoming a leading force in DNA-targeted precision medicine, with a focus on developing anti-gene oligonucleotide therapies that can change the treatment landscape for high-need patient populations.
English 
Italian